Indian drugmakers flood market with cheaper weight-loss medicine versions

The global and Indian markets for anti-obesity drugs are expanding rapidly, driven by breakthrough medications such as Ozempic, Wegovy, Mounjaro and experimental therapies under development. The trend comes as obesity emerges as a growing public health challenge in India, where nearly one in four adults is estimated to be overweight or obese, increasing the risk of diabetes, cardiovascular disease and other chronic illnesses.

Medical experts view the new generation of GLP-1 and related drugs as a significant advance in obesity treatment. Clinical studies have shown that these medications can help patients lose between 10 and 20 percent of their body weight while also improving blood sugar control and lowering the risk of heart-related complications. The availability of more affordable generic versions in India is expected to broaden access and accelerate market growth.

However, the growing popularity of these treatments has sparked concerns among healthcare professionals and policymakers. The drugs remain costly for many patients, often require long-term use to maintain results, and can cause side effects including nausea, vomiting and gastrointestinal discomfort. Experts have also warned against self-medication and the misuse of weight-loss injections by individuals seeking rapid cosmetic results rather than medically supervised treatment.

Critics argue that the increasing reliance on pharmaceutical solutions could divert attention from the importance of sustainable lifestyle changes such as balanced diets, regular physical activity and preventive healthcare. Some fear that the popularity of weight-loss injections may encourage a "quick-fix" mindset rather than addressing the underlying causes of obesity.

As India's obesity drug market is projected to expand significantly in the coming years, regulators and healthcare authorities face the challenge of balancing innovation with safety. Ensuring responsible prescribing practices, preventing misuse, monitoring long-term outcomes and promoting lifestyle interventions alongside medication will be critical to maximizing the benefits of these therapies while minimizing potential risks.